Price
No data yet.
Social Signal Score
Analyst Ratings
1 analystRevenue
$0.00Analyst Estimates
Consensus estimates, not results. Via Financial Modeling Prep.
Company Profile
- CEO
- Daniel Schmitt
- Sector
- Healthcare
- Industry
- Biotechnology
- Employees
- 12
- Beta
- 0.78
- Country
- US
- Piotroski score
- 1 / 9 (Weak)
- Altman Z-score
- -91.84
Financials
Net Income
$-3.42MEBITDA
$-3.44M-12251.8%Free Cash Flow
$-2.95MEPS (diluted)
$-0.14Shares Outstanding (diluted)
24.22M+80.8%Operating Expenses
$3.44MCash & Debt
$2.10MQuote
Valuation & Ratios
Returns & Efficiency
Revenue & Net Income (Annual)
| Fiscal Year | Revenue | Net Income | EPS |
|---|---|---|---|
| 2025 | $0.00 | $-22.23M | $-1.06 |
| 2024 | $0.00 | $-27.29M | $-3.26 |
| 2023 | $0.00 | $-24.74M | $-1.65 |
| 2022 | $0.00 | $-20.16M | $-1.34 |
Valuation
ACTUhas no positive reported earnings per share, so an earnings-multiple projection can't be built for it. Companies are valued on other measures at this stage — revenue growth, cash burn, or book value — none of which this calculator models.
Signal Score (90d)
70-44.74%Social Signal Score
Mentions (6)
- Newsglobenewswire.com·4d ago·Negative
…cal trial in Q1 2027 with daily dosing of elraglusib oral tablet CHICAGO and FORT WORTH, Texas, Nov. 18, 2026 (GLOBE NEWSWIRE) -- Actuate Therapeutics, Inc. (NASDAQ: ACTU) (“Actuate” or the “Company”), a clinical-stage biopharmaceutical company focused on developing therapies for difficult-to-treat cancers, today announced new preclinical data demonstrating that daily oral administration of elraglusib achieved up to 77% tumor growth inhibition as monotherapy in an aggressive melanoma model, with…
View source ↗ - Newsglobenewswire.com·18d ago·Neutral
…ial evaluating Elraglusib Oral Tablet to be initiated in Q1 2027 CHICAGO and FORT WORTH, Texas, Nov. 04, 2026 (GLOBE NEWSWIRE) -- Actuate Therapeutics, Inc. (NASDAQ: ACTU) (“Actuate” or the “Company”), a clinical-stage biopharmaceutical company, focused on developing therapies for the treatment of high-impact, difficult-to-treat cancers, today announced that new preclinical data evaluating oral elraglusib will be presented in a poster at the 38th EORTC-NCI-AACR Symposium on Molecular Targets and…
View source ↗ - Newsglobenewswire.com·20d ago·Negative
Actuate Therapeutics Receives U.S. Notice of Allowance for Patent Covering Elraglusib Oral Tablets Oral tablet form expected to allow Company to optimize patient plasma exposure levels with convenient daily dosing of drug
View source ↗ - Newsglobenewswire.com·26d ago·Neutral
… Announces Pricing of $11.0 Million Underwritten Public Offering CHICAGO and FORT WORTH, Texas, Oct. 27, 2026 (GLOBE NEWSWIRE) -- Actuate Therapeutics, Inc. (NASDAQ: ACTU) (“Actuate” or the “Company”), a clinical-stage biopharmaceutical company focused on developing novel therapies for difficult-to-treat cancers, today announced the pricing of an underwritten public offering of 30,985,900 shares of its common stock and warrants to purchase up to an aggregate of 15,492,950 shares of its common st…
View source ↗ - Newsglobenewswire.com·74d ago·Neutral
…in Combination with RAS Inhibitors Zoldonrasib and Daraxonrasib CHICAGO and FORT WORTH, Texas, Sept. 09, 2026 (GLOBE NEWSWIRE) -- Actuate Therapeutics, Inc. (NASDAQ: ACTU) (“Actuate” or the “Company”), a clinical-stage biopharmaceutical company, focused on developing novel therapies for high-impact, difficult-to-treat cancers, today announced new preclinical data evaluating elraglusib in combination with zoldonrasib (RMC-9805), an investigational RAS(ON) G12D-selective inhibitor, and daraxonrasi…
View source ↗ - Newszacks.com·81d ago·Positive
All You Need to Know About Actuate Therapeutics, Inc. (ACTU) Rating Upgrade to Buy Actuate Therapeutics, Inc. (ACTU) has been upgraded to a Zacks Rank #2 (Buy), reflecting growing optimism about the company's earnings prospects. This might drive the stock higher in the near term.
View source ↗
Earnings
Thu, Mar 25(in 4 months)
Consensus estimate $-0.14 per share
Typical surprise +1.6% (median, so one quarter with a near-zero estimate can't distort it)
- Fri, Nov 13$-0.14 vs $-0.17beat
- Fri, Aug 14$-0.20 vs $-0.20beat
- Thu, May 14$-0.24 vs $-0.23miss
- Thu, Mar 26$-0.18 vs $-0.24beat
- Thu, Nov 13$-0.25 vs $-0.27beat
- Thu, Aug 14$-0.30 vs $-0.19miss
Estimates and results for ACTU via Financial Modeling Prep. Beating consensus says the company cleared the bar analysts set, not that the business grew.
Insider trading
Open-market buys and sells by ACTU officers and directors.
- Bought
- $6.1m
- Sold
- $2.4m
9 trades
11 trades
- Schmitt Daniel Mbought
- Schmitt Daniel Mbought
- Thomson Todd Ssold
- Bios Equity Cof, Lpbought
- Bios Equity Cof, Lpbought
- Kreis Leslie W.bought
- Kreis Leslie W.bought
- Fletcher Aaron G.l.bought
80 further Form 4 entries are share awards, option exercises or shares withheld for tax. Those are compensation, not trades, so they are excluded above. Buying is the stronger signal: an insider spends their own money for one reason. Selling has many innocent explanations — tax, diversifying, a house — so it says far less than it appears to. Via SEC filings.
Congress trades
No disclosed congressional trades in ACTU.
Self-reported filings, amounts as brackets. Via Senate/House disclosures.
